Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 4/6/2019 |
| Start Date: | May 23, 2018 |
| End Date: | March 21, 2019 |
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration: An Ancillary Study to the Age-Related Eye Disease Study-2 (AREDS2)
Background:
Age-related macular degeneration (AMD) is the leading cause of blindness in the United
States. Currently, there is no safe way to obtain cells from the eye to study. But
researchers now can turn other types of cells, like skin or blood, into induced pluripotent
stem (iPS) cells. These can be grown in a lab and turned into other types of cells, like
cells from the eye. This will allow researchers to understand and treat diseases of the eye
such as AMD.
Objectives:
To establish a bank of samples that can be changed into other cell types, such as eye cells,
to better understand diseases such as AMD. Also to test drugs in order to treat various eye
diseases.
Eligibility:
People who provided DNA samples in another protocol (07-EI-0025)
Design:
Participants will be screened with their data from the previous protocol. Participants with
select genetic variants will be chosen and contacted via phone.
Participants will have a punch skin biopsy. The skin will be washed. A numbing medication
will be injected. A small piece of skin will be removed with a biopsy tool. The site will be
covered with a dressing. They will receive instructions on how to care for the area. They
will have follow-up visits if needed for clinical care for the area.
Participants may be asked to return if their first sample did not provide enough cells for
the lab.
Participants sample will be developed into eye cells. The cells will be used to understand
diseases and test new drugs.
Age-related macular degeneration (AMD) is the leading cause of blindness in the United
States. Currently, there is no safe way to obtain cells from the eye to study. But
researchers now can turn other types of cells, like skin or blood, into induced pluripotent
stem (iPS) cells. These can be grown in a lab and turned into other types of cells, like
cells from the eye. This will allow researchers to understand and treat diseases of the eye
such as AMD.
Objectives:
To establish a bank of samples that can be changed into other cell types, such as eye cells,
to better understand diseases such as AMD. Also to test drugs in order to treat various eye
diseases.
Eligibility:
People who provided DNA samples in another protocol (07-EI-0025)
Design:
Participants will be screened with their data from the previous protocol. Participants with
select genetic variants will be chosen and contacted via phone.
Participants will have a punch skin biopsy. The skin will be washed. A numbing medication
will be injected. A small piece of skin will be removed with a biopsy tool. The site will be
covered with a dressing. They will receive instructions on how to care for the area. They
will have follow-up visits if needed for clinical care for the area.
Participants may be asked to return if their first sample did not provide enough cells for
the lab.
Participants sample will be developed into eye cells. The cells will be used to understand
diseases and test new drugs.
Objective: This ancillary study will establish a repository of biospecimens to generate
induced pluripotent stem (iPS) cells that can be differentiated into ocular cell types, to be
used for study of molecular mechanisms of and development of treatments for age-related
macular degeneration (AMD). This repository will allow the cells to be used to perform high
throughput drug screens to identify novel potential therapeutic compounds. Although research
involving multiple different ocular cell types from these patients may be performed, the vast
majority of the work will be centered on the retinal pigment epithelium (RPE) and neural
retina. RPE and/or neural retinal cells generated from the iPS cells of participants with AMD
will be used to analyze molecular mechanisms involved in disease initiation and progression.
Study Population: We plan to recruit 100 participants across multiple sites with AMD from the
original cohort of study participants enrolled in the AREDS2 who are returning for a 10 year
in-clinic study visit and have donated DNA in the AREDS2 study. Up to two participants will
be enrolled at NEI. Participants with the highest genetic burden as well as those with rare
variants will be included in the population.
Design: A 520 blood sample will be collected from 350 participants with specific genetic
variants that are identified prior to the start of the study. Up to 60 participants will be
enrolled at NEI. All of these participants were previously enrolled in the AREDS2 protocol
(07-EI-0025) and they are returning for a 10-year in-clinic study visit for further
phenotyping and for assessing the long-term effects of the ARESD2 supplements. Collected
samples will be used to analyze molecular mechanisms involved in disease initiation and
progression. In addition, the iPS cell-derived ocular cells may be used to perform high
throughput (HTP) drug screens aimed at suppressing the molecular phenotypes of the disease
and to identify potential therapeutic agents for these diseases. This study will typically
require only one visit by each participant.
Outcome Measures: The primary outcome is to develop a repository for iPS cells for
investigators involved in vision research. Secondary outcomes include the assessment of
potential therapies for the treatment of age related macular disorder (AMD). There are no
specific participant-based clinical outcomes for this protocol. Participants will, in
general, be seen only once for this protocol, as this is an ancillary study to the main
study.
induced pluripotent stem (iPS) cells that can be differentiated into ocular cell types, to be
used for study of molecular mechanisms of and development of treatments for age-related
macular degeneration (AMD). This repository will allow the cells to be used to perform high
throughput drug screens to identify novel potential therapeutic compounds. Although research
involving multiple different ocular cell types from these patients may be performed, the vast
majority of the work will be centered on the retinal pigment epithelium (RPE) and neural
retina. RPE and/or neural retinal cells generated from the iPS cells of participants with AMD
will be used to analyze molecular mechanisms involved in disease initiation and progression.
Study Population: We plan to recruit 100 participants across multiple sites with AMD from the
original cohort of study participants enrolled in the AREDS2 who are returning for a 10 year
in-clinic study visit and have donated DNA in the AREDS2 study. Up to two participants will
be enrolled at NEI. Participants with the highest genetic burden as well as those with rare
variants will be included in the population.
Design: A 520 blood sample will be collected from 350 participants with specific genetic
variants that are identified prior to the start of the study. Up to 60 participants will be
enrolled at NEI. All of these participants were previously enrolled in the AREDS2 protocol
(07-EI-0025) and they are returning for a 10-year in-clinic study visit for further
phenotyping and for assessing the long-term effects of the ARESD2 supplements. Collected
samples will be used to analyze molecular mechanisms involved in disease initiation and
progression. In addition, the iPS cell-derived ocular cells may be used to perform high
throughput (HTP) drug screens aimed at suppressing the molecular phenotypes of the disease
and to identify potential therapeutic agents for these diseases. This study will typically
require only one visit by each participant.
Outcome Measures: The primary outcome is to develop a repository for iPS cells for
investigators involved in vision research. Secondary outcomes include the assessment of
potential therapies for the treatment of age related macular disorder (AMD). There are no
specific participant-based clinical outcomes for this protocol. Participants will, in
general, be seen only once for this protocol, as this is an ancillary study to the main
study.
- INCLUSION CRITERIA:
To be eligible, the following inclusion criteria must be met, where applicable.
1. AREDS2 participants who have provided DNA samples. A list will be generated based upon
the results, picking the top GWAS results from this cohort.
2. Participant must understand and sign the protocol s informed consent document.
3. Participant is able to provide 20 ml blood sample.
EXCLUSION CRITERIA:
A participant is not eligible if any of the following exclusion criteria are present.
1. Participant is unable to comply with study procedures.
We found this trial at
14
sites
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
301-496-2563
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Massachusetts Eye & Ear Infirmary Whether you see our physicians at Mass. Eye and Ear's...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
3412 13 Mile Road
Grand Rapids, Michigan 49546
Grand Rapids, Michigan 49546
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Wisconsin-Madison In achievement and prestige, the University of Wisconsin-Madison has long been recognized...
Click here to add this to my saved trials
3412 13 Mile Road
Novi, Michigan 48375
Novi, Michigan 48375
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials